<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33435">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01855919</url>
  </required_header>
  <id_info>
    <org_study_id>14376</org_study_id>
    <secondary_id>F1J-JE-HMGY</secondary_id>
    <nct_id>NCT01855919</nct_id>
  </id_info>
  <brief_title>A Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain</brief_title>
  <official_title>Effect of Duloxetine 60 mg Versus Placebo in Patients With Chronic Low Back Pain in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shionogi and Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy and safety of duloxetine in participants
      with Chronic Low Back Pain (CLBP).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Brief Pain Inventory (BPI) 24-Hour Average Pain Severity Item to Week 14</measure>
    <time_frame>Baseline, Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-Improvement) at Week 14</measure>
    <time_frame>Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Roland Morris Disability Questionnaire (RMDQ-24) to Week 14</measure>
    <time_frame>Baseline, Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in BPI Pain Severity Items and Interference Items Scores to Week 14</measure>
    <time_frame>Baseline, Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Weekly Mean of 24 Hour Average Pain and Worst Daily Pain Severity Scores to Week 14</measure>
    <time_frame>Baseline, Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Reduction of ≥30% and ≥50% in BPI Average Pain Score at Week 14</measure>
    <time_frame>Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Sustained Pain Reduction in BPI Average Pain Score</measure>
    <time_frame>Baseline through Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Global Impression of Severity (CGI-Severity) to Week 14</measure>
    <time_frame>Baseline, Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Beck Depression Inventory-II (BDI-II) to Week 14</measure>
    <time_frame>Baseline, Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 36-Item Short-Form Health Survey (SF-36) to Week 14</measure>
    <time_frame>Baseline, Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Quality of Life Questionnaire-5 Dimension (EQ-5D) to Week 14</measure>
    <time_frame>Baseline, Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Work Productivity and Activity Impairment (WPAI) Instrument to Week 14</measure>
    <time_frame>Baseline, Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) to Week 14</measure>
    <time_frame>Baseline, Week 14</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Fall Events in Fall Questionnaire</measure>
    <time_frame>Baseline to Week 14</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Back Pain Lower Back Chronic</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for first 3 days and 20 mg for last 4 days of week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally once every day for 15 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>Cymbalta</other_name>
    <other_name>LY248686</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with CLBP present for the preceding 6 months or longer

          -  Participants used nonsteroidal anti-inflammatory drugs for CLBP for more than 14 days
             on average per month in the past 3 months and more than 14 days in one month prior to
             screening

          -  Participants having a score of ≥4 on Brief Pain Inventory (BPI) average pain score
             before randomized

          -  Female participants having child-bearing potential must test negative (-) on a
             pregnancy test

        Exclusion Criteria:

          -  Participants have received treatment within the last 30 days with a drug that has not
             received regulatory approval for any indication

          -  Participants having a history of low back surgery

          -  Participants having received epidural steroids, facet block, nerve block or other
             invasive procedures aimed to reduce low back pain within one month prior to screening

          -  Participants who have any difficulties to fulfill diary appropriately

          -  Participants having any previous diagnosis of psychosis, bipolar disorder, or
             schizoaffective disorder

          -  Participants having major depressive disorder as determined using depression module
             of the Mini-International Neuropsychiatric Interview

          -  Participants having primary painful condition due to other than CLBP

          -  Participants being anticipated by the investigator to require use of nonsteroidal
             anti-inflammatory drugs and includes acetaminophen, opioid analgesics, or other
             excluded medication for the duration of the study

          -  Participants being considered as inappropriate for participation to the study for any
             medical or other reason as judged by the investigator

          -  Participants answering &quot;yes&quot; to any of the questions about active suicidal
             ideation/intent/behaviors occurring within the past month (Columbia Suicide Severity
             Rating Scale, Suicide Ideation section - Questions 4 and 5; Suicidal Behavior
             section)

          -  Participants having a positive urine drug screen for any substances of abuse or
             excluded medication

          -  Participants having alanine aminotransferase or aspartate aminotransferase  higher
             than 100 International Units per Liter (IU/L) or total bilirubin higher than 1.6
             milligram per deciliter (mg/dL)

          -  Participants having serum creatinine level higher than 2.0 mg/dL, or had renal
             transplantation or receiving renal dialysis

          -  Participants having uncorrected thyroid disease, uncontrolled narrow-angle glaucoma,
             history of uncontrolled seizures, or uncontrolled or poorly controlled hypertension

          -  Participants have had previous exposure to duloxetine or completed / withdrawn from
             any study investigating duloxetine

          -  Participants having serious or unstable cardiovascular, hepatic, renal, metabolic,
             respiratory, or hematologic illness, symptomatic peripheral vascular disease, or
             other medical condition or psychiatric conditions that, in the opinion of
             investigator, would compromise participation or be likely to lead to hospitalization
             during the course of the study

          -  Participants have known hypersensitivity to multiple medications

          -  Participants having diagnosis seronegative spondyloarthropathy or rheumatoid
             arthritis

          -  Participants taking any excluded medications that cannot be discontinued

          -  Participants treating with a monoamine oxidase inhibitor (MAOI) within 14 days or the
             potential need to use an MAOI during the study or within 5 days of discontinuation of
             study drug

          -  Participants are non-ambulatory or require the use of crutches or a walker

          -  Participants having a history of substance abuse or dependence within the past year,
             excluding nicotine and caffeine

          -  Pregnant participants or participants were breast-feeding, or wished to be pregnant
             during the clinical trial period

          -  Participants cannot use appropriate contraceptive method or do not want to use that
             from screening until one month after the end of administration of the investigational
             drug
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>May 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Low Back Pain</keyword>
  <keyword>CLBP</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Duloxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
